Upregulation of PD-L1 by tumor cells following administration of chemo-radiotherapy (CRT) has been demonstrated in a number of preclinical models (55–57) with an improvement in RR, PFS and median time to death being achieved with the addition of adjuvant durvalumab to CRT in locally advanced, unresectable Non-Small-Cell Lung Cancer as demonstrated in the large phase III PACIFIC study (58). Here, CD274 is linked to neoplasm.